Terms: = Breast cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Treatment
474 results:
1. DB-1310, an ADC comprised of a novel anti-her3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of her3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
2. Targeting HER2/her3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.
Blas PE; Rodriguez ESR; Williams HL; Levin MK; Bell JSK; Pierobon M; Barrett AS; Petricoin EF; O'Shaughnessy JA
Cancer Rep (Hoboken); 2024 Mar; 7(3):e1954. PubMed ID: 38441358
[TBL] [Abstract] [Full Text] [Related]
3. Stellate Ganglion Destruction With Alcohol Versus Thermal Ablation for Chronic Post-Mastectomy Pain: A Randomized Trial.
Thabet TS; Khedr SA
Pain Physician; 2024 Feb; 27(2):E231-E238. PubMed ID: 38324788
[TBL] [Abstract] [Full Text] [Related]
4. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
[TBL] [Abstract] [Full Text] [Related]
5. Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.
Fletcher KA; Alkurashi MH; Lindsay AJ
Breast Cancer Res Treat; 2024 Apr; 204(3):631-642. PubMed ID: 38228924
[TBL] [Abstract] [Full Text] [Related]
6. Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers.
Joyce R; Pascual R; Heitink L; Capaldo BD; Vaillant F; Christie M; Tsai M; Surgenor E; Anttila CJA; Rajasekhar P; Jackling FC; Trussart M; Milevskiy MJG; Song X; Li M; Teh CE; Gray DHD; ; Smyth GK; Chen Y; Lindeman GJ; Visvader JE
Nat Cell Biol; 2024 Jan; 26(1):138-152. PubMed ID: 38216737
[TBL] [Abstract] [Full Text] [Related]
7. Sequencing Antibody Drug Conjugates in breast cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract] [Full Text] [Related]
8. Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in breast cancer Brain Metastasis.
Lim M; Fletcher NL; Saunus JM; McCart Reed AE; Chittoory H; Simpson PT; Thurecht KJ; Lakhani SR
Mol Pharm; 2023 Dec; 20(12):6169-6183. PubMed ID: 37970806
[TBL] [Abstract] [Full Text] [Related]
9. Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide.
Fletcher KA; Alkurashi MH; Lindsay AJ
Invest New Drugs; 2024 Feb; 42(1):14-23. PubMed ID: 37957513
[TBL] [Abstract] [Full Text] [Related]
10. her3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of cancer.
Majumder A
Cells; 2023 Oct; 12(21):. PubMed ID: 37947595
[TBL] [Abstract] [Full Text] [Related]
11. Architecture and topologies of gene regulatory networks associated with breast cancer, adjacent normal, and normal tissues.
Kumar S; Vindal V
Funct Integr Genomics; 2023 Oct; 23(4):324. PubMed ID: 37878223
[TBL] [Abstract] [Full Text] [Related]
12. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract] [Full Text] [Related]
13. Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With breast cancer.
Hassanzadeh Makoui M; Mobini M; Fekri S; Geranpayeh L; Moradi Tabriz H; Madjd Z; Kalantari E; Hosseini M; Hosseini M; Golsaz-Shirazi F; Jeddi-Tehrani M; Zarnani AH; Amiri MM; Shokri F
Clin Breast Cancer; 2024 Jan; 24(1):e9-e19.e9. PubMed ID: 37863762
[TBL] [Abstract] [Full Text] [Related]
14. Patritumab Deruxtecan (her3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic breast cancer: A Multicenter, Phase I/II Trial.
Krop IE; Masuda N; Mukohara T; Takahashi S; Nakayama T; Inoue K; Iwata H; Yamamoto Y; Alvarez RH; Toyama T; Takahashi M; Osaki A; Saji S; Sagara Y; O'Shaughnessy J; Ohwada S; Koyama K; Inoue T; Li L; Patel P; Mostillo J; Tanaka Y; Sternberg DW; Sellami D; Yonemori K
J Clin Oncol; 2023 Dec; 41(36):5550-5560. PubMed ID: 37801674
[TBL] [Abstract] [Full Text] [Related]
15. Axillary ultrasound for predicting response to neoadjuvant treatment in breast cancer patients-a single institution experience.
Pislar N; Gasljevic G; Music MM; Borstnar S; Zgajnar J; Perhavec A
World J Surg Oncol; 2023 Sep; 21(1):292. PubMed ID: 37715188
[TBL] [Abstract] [Full Text] [Related]
16. Inhibiting her3 Hyperphosphorylation in HER2-Overexpressing breast cancer through Multimodal Therapy with Branched Gold Nanoshells.
Villar-Alvarez E; Golán-Cancela I; Pardo A; Velasco B; Fernández-Vega J; Cambón A; Al-Modlej A; Topete A; Barbosa S; Costoya JA; Taboada P
Small; 2023 Dec; 19(50):e2303934. PubMed ID: 37632323
[TBL] [Abstract] [Full Text] [Related]
17. Desmocollin-1 is associated with pro-metastatic phenotype of luminal A breast cancer cells and is modulated by parthenolide.
Lapcik P; Sulc P; Janacova L; Jilkova K; Potesil D; Bouchalova P; Müller P; Bouchal P
Cell Mol Biol Lett; 2023 Aug; 28(1):68. PubMed ID: 37620794
[TBL] [Abstract] [Full Text] [Related]
18. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K; Eli LD; Wildiers H; Hurvitz SA; Guerrero-Zotano A; Unni N; Brufsky A; Park H; Waisman J; Yang ES; Spanggaard I; Reid S; Burkard ME; Vinayak S; Prat A; Arnedos M; Bidard FC; Loi S; Crown J; Bhave M; Piha-Paul SA; Suga JM; Chia S; Saura C; Garcia-Saenz JÁ; Gambardella V; de Miguel MJ; Gal-Yam EN; Rapael A; Stemmer SM; Ma C; Hanker AB; Ye D; Goldman JW; Bose R; Peterson L; Bell JSK; Frazier A; DiPrimeo D; Wong A; Arteaga CL; Solit DB
Ann Oncol; 2023 Oct; 34(10):885-898. PubMed ID: 37597578
[TBL] [Abstract] [Full Text] [Related]
19. The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the treatment of Early-Stage breast cancer.
Bhardwaj PV; Abdou YG
Oncologist; 2023 Oct; 28(10):832-844. PubMed ID: 37597245
[TBL] [Abstract] [Full Text] [Related]
20. High neuroticism is associated with common late adverse effects in a nationwide sample of long-term breast cancer survivors.
Dahl AA; Smedsland SK; Vandraas KF; Bøhn SK; Falk RS; Kiserud CE; Reinertsen KV
Breast Cancer Res Treat; 2023 Nov; 202(1):97-104. PubMed ID: 37528264
[TBL] [Abstract] [Full Text] [Related]
[Next]
